GTPBP10 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population designed to disrupt the GTPBP10 gene, providing a loss-of-function model for investigating mitochondrial ribosome assembly and translation. This product consists of a heterogenous pool of edited cells, ensuring robust representation of knockout effects without clonal isolation. The use of CRISPR/Cas9-mediated gene disruption enables targeted ablation of GTPBP10 function, allowing researchers to study its role in mitochondrial biology and related pathological conditions.
The host cell line, HeLa, is a widely used human cervical adenocarcinoma model derived from an HPV18-positive tumor. These cells exhibit robust growth characteristics and are extensively characterized in cancer research, including studies of metabolism, signaling, and drug response. HeLa cells maintain active oxidative phosphorylation alongside glycolysis, making them particularly suitable for examining mitochondrial defects in a cancerous context. Their HPV18-positive status provides additional relevance for viral oncogenesis and host-pathogen interaction studies.
GTPBP10 encodes a mitochondrial GTPase that is essential for the assembly of the large mitochondrial ribosomal subunit. Its molecular function is tightly integrated into the mitochondrial translation machinery: it interacts with ribosomal protein MRPL44, the GTPase GTPBP5, and mitochondrial HSP70 to facilitate ribosome biogenesis. GTPBP10 is regulated by key transcriptional regulators of mitochondrial biogenesis, including TFAM, NRF1, and PGC-1??. Downstream, its activity is critical for the synthesis of mitochondrial-encoded oxidative phosphorylation (OXPHOS) subunits such as ND1 (complex I) and COX1 (complex IV), as well as mtDNA-encoded tRNAs. Disruption of GTPBP10 therefore impairs mitochondrial translation, leading to defective respiratory chain function and reduced cellular energy production.
In the HeLa cancer cell model, GTPBP10 knockout creates a metabolic vulnerability by uncoupling mitochondrial protein synthesis from energy demand. This is particularly significant for studying the interplay between mitochondrial dysfunction and cancer cell proliferation, as HeLa cells rely on functional OXPHOS for survival under certain stress conditions. The polyclonal knockout population mirrors heterogeneous tumor environments, offering a realistic platform for examining metabolic adaptation and the role of mitochondrial ribosome biogenesis in oncogenic processes.
This product is suitable for a wide range of research applications, including the investigation of mitochondrial diseases, hearing loss, developmental delay, and cancer metabolism. Typical experimental assays include Western blotting to assess mitochondrial protein levels, seahorse respirometry to measure oxygen consumption rates, RT-qPCR for quantifying mtDNA-encoded transcripts, and mitotracker staining coupled with flow cytometry to evaluate mitochondrial membrane potential. These cells can also be employed in drug screening campaigns targeting mitochondrial dysfunction. For additional information or customized products, please contact Ascent Research.
